BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36384247)

  • 1. Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL).
    Tucci A; Merli F; Fabbri A; Marcheselli L; Pagani C; Puccini B; Marino D; Zanni M; Pennese E; Flenghi L; Arcari A; Botto B; Celli M; Mammi C; Re A; Campostrini G; Tafuri A; Zilioli VR; Cencini E; Sartori R; Bottelli C; Merli M; Petrucci L; Gini G; Balzarotti M; Cavallo F; Musuraca G; Luminari S; Rossi G; Spina M
    Haematologica; 2023 Apr; 108(4):1083-1091. PubMed ID: 36384247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The elderly prognostic index predicts early mortality in older patients with diffuse large B-cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana Linfomi.
    Cencini E; Tucci A; Puccini B; Cavallo F; Luminari S; Usai SV; Fabbri A; Pennese E; Marino D; Zilioli VR; Balzarotti M; Petrucci L; Tafuri A; Arcari A; Botto B; Zanni M; Hohaus S; Sartori R; Merli M; Gini G; Al Essa W; Musurca G; Tani M; Nassi L; Daffini R; Mammi C; Marcheselli L; Bocchia M; Spina M; Merli F
    Hematol Oncol; 2023 Feb; 41(1):78-87. PubMed ID: 36177902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma.
    Arcari A; Rigacci L; Tucci A; Puccini B; Usai SV; Cavallo F; Fabbri A; Balzarotti M; Pelliccia S; Luminari S; Pennese E; Zilioli VR; Mahmoud AM; Musuraca G; Marino D; Sartori R; Botto B; Gini G; Zanni M; Hohaus S; Tarantini G; Flenghi L; Tani M; Di Rocco A; Merli M; Vallisa D; Pagani C; Nassi L; Dessì D; Ferrero S; Cencini E; Bernuzzi P; Mammi C; Marcheselli L; Tabanelli V; Spina M; Merli F
    Blood Adv; 2023 Aug; 7(15):4160-4169. PubMed ID: 37276080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of elderly patients with diffuse large B-cell lymphoma: aggressive therapy is a reasonable approach for 'unfit' patients classified by comprehensive geriatric assessment.
    Yoshida M; Nakao T; Horiuchi M; Ueda H; Hagihara K; Kanashima H; Inoue T; Sakamoto E; Hirai M; Koh H; Nakane T; Hino M; Yamane T
    Eur J Haematol; 2016 Apr; 96(4):409-16. PubMed ID: 26084899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Considerations for the Treatment of Diffuse Large B Cell Lymphoma in the Elderly.
    Khan Y; Brem EA
    Curr Hematol Malig Rep; 2019 Aug; 14(4):228-238. PubMed ID: 31228094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana Linfomi.
    Arcari A; Tabanelli V; Merli F; Marcheselli L; Merli M; Balzarotti M; Zilioli VR; Fabbri A; Cavallo F; Casaluci GM; Tucci A; Puccini B; Pennese E; Di Rocco A; Zanni M; Flenghi L; Gini G; Sartori R; Chiappella A; Usai SV; Tani M; Marino D; Arcaini L; Vallisa D; Spina M
    Br J Haematol; 2023 May; 201(4):653-662. PubMed ID: 36733229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy.
    Huntington SF; Talbott MS; Greer JP; Morgan DS; Reddy N
    Leuk Lymphoma; 2012 Aug; 53(8):1461-8. PubMed ID: 22260160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.
    Chiappella A; Tucci A; Castellino A; Pavone V; Baldi I; Carella AM; Orsucci L; Zanni M; Salvi F; Liberati AM; Gaidano G; Bottelli C; Rossini B; Perticone S; De Masi P; Ladetto M; Ciccone G; Palumbo A; Rossi G; Vitolo U;
    Haematologica; 2013 Nov; 98(11):1732-8. PubMed ID: 23812930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group.
    Jurczak W; Ochrem B; Giza A; Zimowska-Curyło D; Górecki T; Boguradzki P; Knopińska-Posłuszny W; Stella-Hołowiecka B; Walewski J; Joks M; Wróbel T; Zaucha JM
    Pol Arch Med Wewn; 2015; 125(10):741-8. PubMed ID: 26334344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma.
    Liu P; Han Y; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Zhou LQ; Yang JL; Yang S; Wen TY; Shi YK
    Chin Med J (Engl); 2019 Aug; 132(15):1807-1814. PubMed ID: 31335477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy.
    Tucci A; Ferrari S; Bottelli C; Borlenghi E; Drera M; Rossi G
    Cancer; 2009 Oct; 115(19):4547-53. PubMed ID: 19562776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi.
    Merli F; Luminari S; Tucci A; Arcari A; Rigacci L; Hawkes E; Chiattone CS; Cavallo F; Cabras G; Alvarez I; Fabbri A; Re A; Puccini B; Barraclough A; Delamain MT; Ferrero S; Usai SV; Ferrari A; Cencini E; Pennese E; Zilioli VR; Marino D; Balzarotti M; Cox MC; Zanni M; Di Rocco A; Lleshi A; Botto B; Hohaus S; Merli M; Sartori R; Gini G; Nassi L; Musuraca G; Tani M; Bottelli C; Kovalchuk S; Re F; Flenghi L; Molinari A; Tarantini G; Chimienti E; Marcheselli L; Mammi C; Spina M
    J Clin Oncol; 2021 Apr; 39(11):1214-1222. PubMed ID: 33577377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study.
    Carella AM; de Souza CA; Luminari S; Marcheselli L; Chiappella A; di Rocco A; Cesaretti M; Rossi A; Rigacci L; Gaidano G; Merli F; Spina M; Stelitano C; Hohaus S; Barbui A; Puccini B; Miranda EC; Guida A; Federico M
    Leuk Lymphoma; 2013 Jan; 54(1):53-7. PubMed ID: 22712840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial.
    Xu PP; Fu D; Li JY; Hu JD; Wang X; Zhou JF; Yu H; Zhao X; Huang YH; Jiang L; Liu F; Su LP; Chen ZW; Zeng QS; Chen JP; Fang MY; Ma J; Liu T; Song YP; Yu K; Li Y; Qiu LG; Chen XQ; Gu J; Yan JS; Hou M; Huang HY; Wang L; Cheng S; Shen Y; Xiong H; Chen SJ; Zhao WL
    Lancet Haematol; 2019 Jun; 6(6):e328-e337. PubMed ID: 31126528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi.
    Merli F; Cavallo F; Salvi F; Tucci A; Musuraca G; Nassi L; Merli M; Tani M; Gini G; Ferrari A; Molinari AL; Liberati AM; Conconi A; Matteucci P; Bari A; Scalone R; Ferrero S; Zanni M; Mammi C; Luminari S
    J Geriatr Oncol; 2020 Jan; 11(1):37-40. PubMed ID: 31296461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients.
    Pfreundschuh M; Murawski N; Zeynalova S; Ziepert M; Loeffler M; Hänel M; Dierlamm J; Keller U; Dreyling M; Truemper L; Frickhofen N; Hünerlitürkoglu AN; Schmitz N; Pöschel V; Rixecker T; Berdel C; Rübe C; Held G; Zwick C
    Br J Haematol; 2017 Nov; 179(3):410-420. PubMed ID: 28990173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features and outcome of the patients with sinonasal tract diffuse large B-cell lymphoma in the pre-rituximab and rituximab eras.
    Vähämurto P; Mannisto S; Pollari M; Karjalainen-Lindsberg ML; Mäkitie AA; Leppä S
    Eur J Haematol; 2019 Jun; 102(6):457-464. PubMed ID: 30834564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The beneficial effect of Escalated-R-CHOP-21 for the treatment of diffuse large B-cell lymphoma in elderly male patients: A propensity-matched cohort study.
    He HX; Gao Y; Bai B; Wang XX; Li JB; Huang C; Mao JY; Ping LQ; Rong QX; He YX; Huang H; Cai QQ; Li ZM; Jiang WQ; Huang HQ
    Cancer Med; 2021 Nov; 10(21):7650-7664. PubMed ID: 34581023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.